Summary of: Khozin S, Carson KR, Zhi J, Tucker MG, Lee SE, Light DE, Curtis MD, Bralic M, Kaganman I, Gossai A, Hofmeister PP, Torres AZ, Miksad RA, Blumenthal GM, Pazdur R, Abernethy AP. Real‐world outcomes of patients with metastatic non‐small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following US regulatory approval. The Oncologist. 24 (5):648-656. 2019.
As new classes of therapies are approved and enter clinical practice, studies using real-world data can provide valuable information on generalizability of clinical trial evidence. Co-authored with the FDA, this study analyzed a large and recent real-world cohort to estimate real-world survival following treatment with PD-1 inhibitors, nivolumab and pembrolizumab, in the first year following regulatory approval for NSCLC.